Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$9.35 USD

9.35
4,422,333

-0.26 (-2.71%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $9.42 +0.07 (0.75%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Novavax

by Zacks Equity Research

Pfizer, BioNTech, Moderna and Novavax are included in this Analyst Blog.

Kinjel Shah headshot

Vaccine Stocks Down After Biden Says Pandemic is Over

by Kinjel Shah

BioNTech (BNTX), Moderna (MRNA) and Novavax (NVAX) stocks decline 8.6%, 7.1% and 6.5%, respectively.

Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?

by Zacks Equity Research

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Novavax (NVAX) Flat As Market Sinks: What You Should Know

by Zacks Equity Research

Novavax (NVAX) closed the most recent trading day at $32.55, making no change from the previous trading session.

Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More

by Zacks Equity Research

Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.

Novavax (NVAX) Gets EU Nod for COVID-19 Booster Jab in Adults

by Zacks Equity Research

Novavax (NVAX) gets authorization from the European Union to use its COVID-19 vaccine as a booster dose in adults.

Novavax (NVAX) Down 29.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?

by Zacks Equity Research

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax's (NVAX) COVID-19 Jab Gets Approval in Switzerland

by Zacks Equity Research

Novavax (NVAX) receives expanded temporary authorization for Nuvaxovid, its COVID-19 vaccine, in Switzerland for adolescents aged 12 to 17 and as a booster in adults aged 18 years and above.

Novavax's (NVAX) COVID-19 Booster Gets CHMP Recommendation

by Zacks Equity Research

The European Medicines Agency's CHMP recommends expanded conditional marketing authorization for Novavax's (NVAX) COVID-19 vaccine as a booster for adults.

Ekta Bagri headshot

PFE, BNTX and MRNA Omicron Boosters Get Positive CHMP Opinion

by Ekta Bagri

Pfizer (PFE) /BioNTech (BNTX) and Moderna (MRNA) get positive CHMP opinion for Omicron-targeting bivalent booster.

Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Biotech Stock Roundup: GILD, BLUE, AXSM's Drug Approvals, FHTX Study Update & More

by Zacks Equity Research

Regulatory updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.

Novavax (NVAX) COVID-19 Vaccine Gets FDA Nod for Adolescents

by Zacks Equity Research

Post the label expansion by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in individuals aged 12 years and older in the United States.

Biotech Stock Roundup: GILD's Drug News, NVAX & MRNA COVID-19 Vaccine Updates

by Zacks Equity Research

Regulatory and pipeline updates from Gilead (GILD) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.

Novavax (NVAX) Seeks FDA Authorization for COVID-19 Booster Dose

by Zacks Equity Research

Novavax (NVAX) seeks label expansion from the FDA for its COVID-19 vaccine as a booster dose in adults. The vaccine is authorized as a primary two-dose regimen in adults.

Novavax's (NVAX) COVID Vaccine Aids Growth, Overdependence Ails

by Zacks Equity Research

Currently, Novavax (NVAX) has only one marketed product in its portfolio, its protein-based COVID-19 vaccine. However, it is lagging in competition behind mRNA-based vaccines.

Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.

Bausch (BHC) Q2 Earnings & Sales Miss, View Cut, Stock Down

by Zacks Equity Research

Bausch (BHC) Q2 earnings and sales miss in the second quarter. The company cuts its annual guidance due to the uncertainties in the overall operating environment.

Stock Market News for Aug 10, 2022

by Zacks Equity Research

U.S. stocks ended lower on Tuesday triggered by a selloff in semiconductor and tech stocks, following disappointing results from a batch of big corporates as investors await key inflation data that could lead the Fed to continue with steep rate hikes.

Novavax (NVAX) Q2 Earnings Miss, Cuts '22 Sales Guidance by Half

by Zacks Equity Research

Novavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market trading after management slashes revenue guidance for 2022 by half.

Reata (RETA) Q2 Earnings Miss, Revenues Down Y/Y, Stock Down

by Zacks Equity Research

Reata (RETA) reports a wider-than-expected loss in the second quarter of 2022, while revenues miss estimates. Stock falls after updates on pipeline programs.

Apellis (APLS) Q2 Earnings and Sales Miss Estimates, Stock Down

by Zacks Equity Research

Apellis' (APLS) missed earnings and sales estimates in the second quarter of 2022. Consequently, the stock declines.

Novavax (NVAX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of -218.51% and 82.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research

Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts. CLVS faces the risk of a cash crunch.